Followers | 300 |
Posts | 13,009 |
Boards Moderated | 0 |
Alias Born | 01/30/2013 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BMSN is a MONEY. MAKER. Strap in folks!
HOLY SH!T THIS IS SUCH A GORGEOUS SETUP
If you're not in, tomorrow is your day. BUY AND BANK!
HOLY CRAP if this isn't a MONEY MAKER setup, I've never seen one in my life!
Longs will be swimming in profits soon.
STSI will be $4+ by June.
People who are buying right now will be made rich by this stock.
The product is groundbreaking and that's all the matters. Don't let the fivolous drama and emotional traders skew your vision of what is ahead.
I love buying up these value priced shares! Cheap profits are the best kind.
Cheers all.
This stock is about to make a lot of people very happy, very soon.
YO YOU THINK IF I AXT DA ATTERNIE GENRAL FER MY CHEDDA BACK HE HOOK ME UP?
DIS SOME WEEK SH*T HERR WE GOT LYED TO YO
WATCH FOR THE MEGABOUNCE!
That is certainly not how I would handle it...unless I had tons of confidence in (near) future price performance.
Different loss mitigation strategies for different folks, I'spose.
Good luck.
The word is out. Big 'ol spike tomorrow! Huge promo campaign in effect. We know what this thing does! Excited for tomorrow guys!
What a craptastic show this was today!
So - should I be placing a market order? Someone give me the push I need. I don't have time to research this this morning. Thanks guys.
Yessir. Been gobbling up shares here and there for the last few weeks. I think we all see what's ahead at this point : )
Get ready for the ride folks.
This looks to be a massive run setup. Good luck guys!
Beautiful post marked by strong logic and reasoning. I wish this type of post was more prevelant on this board.
Cheers, Rider.
Yes. Next week could turn out to be a banger. Hold you britches folks, we're bustin upward!
Close at .239
No worries. This sort of thing is exceedingly common.
Alert went out yesterday at the selloff. Reccommended buy was at 1.25 before close, target 1.73 met this AM. Follow if you want to receive direct messages on the fly. My daily picks called the Stellar Playwatch are made public but on delay and without the specifics.
Cheers folks.
Just a heads up guys: My twitter followers are up over 40% this morning on my recent alerts including PLUG.
Orion_Tickers
Indeed. Great read, Jay. Thanks!
Which is exactly why now is such a great opportunity!
You will pick up on these things eventually. No biggie.
Smart investors are buying because they know that none of that matters when they have a product that is jawdroppingly effective.
This is not an emotional game. Sales are going through the roof and that is the operative information; not this tidbits of drama that no one will remember or care about in 2 weeks.
Star Scientific has received positive preliminary results from an investigational study of the effects of anatabine in an animal model of idiopathic inflammatory bowel disease, Crohn’s disease, and ulcerative colitis. Performed by researchers in the University of Virginia’s Department of Medicine, the study assessed the effects of anatabine administration on clinical and histologic manifestations of colitis in a mouse model of colonic inflammation, which possessed many features of a major form of human inflammatory bowel disease.
The animal model of inflammatory bowel disease – in which bowel inflammation is created in mice through administering a chemical known as DSS (dextran sodium sulphate) in their drinking water – was chosen as a well-established and highly reproducible colonic inflammation model. Further, the model enabled an examination of the effect of anatabine on inflammation’s development and severity (colitis prevention) and on recovery from inflammation and the repair of tissue damage (colitis treatment).
It was shown in preliminary results from the prevention phase that animals given anatabine in their drinking water statistically had a score significantly lower (p < 0.05) in the primary clinical disease activity index than the mice receiving only DSS. The disease activity index is the summation of scores from three parameters assessed on a daily basis: weight loss, stool consistency, and hematochezia (blood in the stool). Lower scores demonstrate lower levels of disease activity. Diarrhea and watery stool were significantly reduced during induction of the inflammatory condition with anatabine treatment. It was established that anatabine supplementation after inflammation was less conclusive, as mice in both the anatabine group and the control groups decreased the amount of water they drank by almost half during the first few days of the recovery regimen. The amount of anatabine received by the anatabine-treated set of mice was, therefore, much lower than intended during recovery.
This study’s initial results imply that anatabine dietary supplementation may prevent flare up of ulcerative colitis or reduce the severity of symptoms in vulnerable individuals. Though results from the longer-term treatment phase were inconclusive, the marked reduction in clinical manifestations of some features of bowel inflammation with preventative treatment implies that anatabine supplementation may interfere with the excessive and prolonged production of inflammatory molecules leading to these clinical outcomes.
The work being conducted at the University of Virginia is ongoing to determine whether anatabine administration interfered with the expression of pro-inflammatory cytokines and other markers of inflammation in gastrointestinal tissue samples. A study of the safety and effects of anatabine supplementation in human ulcerative colitis may be warranted, based on the initial primary results of this preclinical study.
“Animal models of human disease are not always predictive of benefits in humans, but when individual patient reports are consistent with an animal model in a controlled laboratory study, the findings reinforce each other,” said Dr. Curtis Wright, medical and clinical director of Rock Creek Pharmaceuticals. “We provided the study materials and appropriate funding to the University of Virginia in support of the investigators’ interest in this area and are very pleased with the results, which are consistent with the individual case reports of benefit we have received from physicians and patients describing their experiences with Anatabloc. We hope the University may consider that the time has come for a human clinical trial, and we will follow their research closely.”
For more information, visit www.starscientific.com
http://www.smallcapnetwork.com/Star-Scientific-Inc-STSI-and-Subsidiary-Report-on-the-Effects-of-Anatabine-in-Animal-Model/s/via/19047/blog/view/p/mid/1/id/288/
Anatabloc®: Explosive trending - Popularity skyrockets in 2013
http://www.google.com/trends/explore#q=anatabloc
Smart traders know what this means for investors.
$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
STSI$ HOME TO GROUNDBREAKING PHARMA,GNC PRODUCT OF THE YEAR:
http://anatabloc.com/home/
Double-blind is the standard.
FREE STSI Trading Tip:
IF YOU ARE A LOGICAL TRADER you have learned to defend a play on your emotions and focus on what matters.
Logical investors know Anatabloc is a groundbreaking pharmaceutical. Smart investors are buying shares.
THE PRODUCT IS THE $$$$; THE $$$$ IS STSI.
Anatabloc® IS $ Investors!
Ashley Vivian, model, praises Anatabloc® by Star Scientific, Inc(STSI$):
Ashley Leigh Vivian @AshleyLVivian: @Anatabloc, dr's told me I would be on thyroid medication the rest of my life. WRONG. No more #Armour. Thanku Dr Mike and thanku #Anatabloc
Anatabloc® was recognized by GNC as the Wellness Winner in the category of Best Product Innovation for 2012.
$STSI$ Star Scientific, Inc. New Peer Review Credibility From Johns Hopkins Could Drive Star Scientific Shares Higher
http://tinyurl.com/STSIBreakingNews
Hypothesis no longer: Johns Hopkins scientists now believe they know why Star Scientific's (CIGX) anatabine compound Anatabloc works. Newly presented thyroid research from the peer reviewed journal Endocrinology makes the case. The implications could drive shares sharply higher as peer reviewed substantiation brings new heights of credibility to the science. See below for context and amplification.
This is important breakthrough news from Johns Hopkins University School of Medicine (where the thyroid research and studies have been funded by a grant from the Walton Family Foundation), so slip on your science hat and stay with me on this. The implications from the medical community will now carry new weight as they will be able to officially discern the kind of conditions that anatabine/Anatabloc could be effective in treating.
Autoimmune (so-called "Hashimoto") thyroiditis, first reported in 1912 and considered a rarity until the mid-1950s, has now become the most common of over 100 autoimmune diseases. The list is available here. A Google search of thyroid disease brought up 7,500,000 results.
What is especially interesting is that these autoimmune conditions are precisely those Anatabloc seems to benefit. The multitude of users of Anatabloc already know that it works - so now it becomes "official." Get the picture? Read on.
I have been following and writing about CIGX for over two years, and the shares have gone up over this time frame from just over $1.00 to Friday's close of $4.05 (the shares traded above $5.00 last year and more recently in early July). Obviously the stock has been a big winner, and the science supporting the story has developed to ever more established heights of the 'nigh astonishing': it has progressed from the genesis of discovery to testing, to peer review, to more testing and now to explanation in the leading journal Endocrinology as to "why" it's believed to work.
Human studies remain to be announced; however, Star has said in this regard: "The current impressive results achieved by the Johns Hopkins team strongly support the first look at the thyroid data in man, which we anticipate will be available in the third quarter."
It should be noted that nonbelievers are plentiful regarding the shares of CIGX, as there is a big short interest of 23,622,933 shares, a large percentage of which has been around for well over two years. The number of shares short is up 1,789,378 shares from the last reporting period of two weeks prior. My comment is that much has changed over the last year with the above mentioned impressive news related to anatabine / Anatabloc and it's now a whole new ball game. Shorts should be worried as the remarkable science continues to advance.
Last Tuesday, July 17, in the freshly released Endocrine Society journal Endocrinology, a peer reviewed research abstract was published by the Department of Pathology, Divisions of Endocrinology and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, and the Feinstone Department of Molecular Microbiology and Immunology (P.C.) of the Johns Hopkins Bloomberg School of Public Health.
ANATABLOC: "WOW! I'm absolutely loving the way I've been waking up in the morning, hitting the weightroom a couple hours later, and being able to do both of these things without any tendon pain at all. Wow!"
"I can't believe that after 20 years of suffering from tendonitis, I finally come across a product that actually works as advertised! I can't tell you how much money i've spent from going to the Rheumatalogist for cortasone shots (or whatever it is he shoots into me). Heck, there were even plenty of times where he hadn't even hit the right spot and I ended up having to go right back to him a couple weeks later! On top of the doctor visits, I also prided myself on eating good and taking various vitams every morning. This may well have been good for me but it did nothing for my tendonitis.
I've been taking this product now for 10 days and I have to say that I'm absolutely loving the way I've been waking up in the morning, hitting the weightroom a couple hours later, and being able to do both of these things without any tendon pain at all. Wow!
Yes this product may be expensive, but for me, it's still cheaper than going to the doctor and having to spend upwards of 300+ dollars a visit.
I've already recommended this to a couple people I work with, so yes, I'd do the same for you as well.
Oh yeah, as far as my daily dose goes, I took 4 per day the first 7 days, then dropped to 3. So far so good!"
Star Scientific shares drop, offering a GOLDEN opportunity to investors.
Star Scientific shares drop, traders buy!
Successful Human Trials Of Star Scientific's Anatabloc Clarifies Risk And Could Drive Share Price
Due to Dr. Paul Ladenson's appointment as Director of Endocrinology and Metabolism at Johns Hopkins, I made the assumption that Johns Hopkins was therefore associated at the institutional level in Star Scientific's ASAP Thyroid clinical trial. It has now become clear that while Dr. Ladenson is the head clinical consultant to Star for the ASAP trial, the relationship between Dr. Ladenson and Star Scientific does not extend to Johns Hopkins as an institution. I regret any confusion, and I am pleased to correct this error below.
Massive Risk Reduction
Last Monday's press release regarding the proof of concept and efficacy of anatabine as employed in human thyroiditis trials by Rock Creek Pharmaceuticals in conjunction with Dr. Paul Ladenson, who acts as a key clinical consultant for Star, clarifies to a large degree the science risks of Star Scientific's (STSI) over-the-counter compound Anatabloc. Because of the $20 million money raise in October, the company's cash now totals about $30 million and its burn rate has been recently cut roughly in half. The science and financial risk potential has now been all but muted.
Risk #1 - The New Data from Human Trials
The Science in Crescendo
cres·cen·do
a. A steady increase in intensity or force
b. The climactic point or moment after such a progression
Dr. Paul Ladenson is the lead clinical consultant for the so-called ASAP* trial. The ASAP (Anatabloc Supplementation Autoimmune Prevention) Human Thyroid Study (in nine locations) analyzes the impact of anatabine dietary supplementation on thyroid health. The ASAP thyroid study was planned as a human follow-up of a successful animal study, "Anatabine Ameliorates Experimental Autoimmune Thyroiditis, Endocrinology. 2012 September. Dr. Ladendon said:
Data from this rigorously conducted, placebo-controlled, double blind trial show that anatabine-treated subjects had progressive decreases in circulating thyroglobulin antibody levels, which became significant by the end of the trial.
[Initial results for all study subjects suggest that dietary supplementation with anatabine ameliorates the immune system's targeting of the thyroid gland in autoimmune thyroiditis.]
Dr. Ladenson has previously stated that:
Aside from RCP-006 [anatabine - now known as Anatabloc] there is no known compound that stops thyroiditis.
Risk #2 - Efficacy and Proof of Concept
Prior to Monday's press regarding the successful Rock Creek / Johns Hopkins human trials of anatabine there was always the possibility that the Star compound would not be effective in humans even though there are numerous corroborating animal studies and extensive anecdotal personal testimonials to that effect. That concern is now off the table. We now KNOW that anatabine works, and it has worked on all study subjects. To be sure, the human study results have yet to be peer-reviewed, but that will come. Next will be the submissions to the New England Journal of Medicine, Journal of Clinical Endocrinology and the European Journal of Pharmacology, etc... With Dr. Ladenson tendering of the human study/data result, peer review acceptance, review and publication in an important journal, should follow in due course.
"I have used Anatabloc every day for over three (3) weeks, using two (2) tablets after every meal, my rhematoid arthritis pain has gone almost completely away. I forget that I have the pain and do things I used to do before the pain, yes, it does still pain when I go beyond normal. However that too is going away and I suspect that it will be gone away as each day is better and better. It does work and you need a positive attitude as always with any item you try"
Dr. Wilson explains: "Anatabloc turns that chronic low grade inflammation off. That's why people with Crohn's disease, fibromyalgia show a marked response. From what I have been doing clinically, from what I've seen, that's one of its most effective areas.
Dr. Dale Wilson - 810-342-1725
Anatabloc: A solution to chronic pain
By Catherine Bodak, TV5
Yes, according to the makers of a product called "Anatabloc."
"I'm just so excited, I've got to tell everybody about it," says Cheryl Reilly.
Reilly is a Midland resident who spent years suffering from Crohn's Disease and Fibromyalgia. Now she claims her days of persistent pain are behind her. She credits a dietary supplement known as Anatabloc.
"My husband could not even touch my skin," Reilly explains, "I mean it was just too painful for anyone to even hug me."
Reilly and her husband have been married for 22 years and they have two daughters in college. Every day was a struggle for her when she was dealing the chronic pain.
"Oh, it was horrible," Reilly said. "I mean I would be in bed and think I was fine. I would get up to walk across the room to leave my bedroom and take two steps and I would be so exhausted and in so much pain I would just crawl back in bed."
Reilly took part in a clinical trial of Anatabloc under the care of Dr. Dale Wilson. He is in charge of the local portion of a national study on Anatabloc.
"At this stage in my career, to be doing something like this is really a thrilling for me," said Dr. Wilson.
The creators of Anatabloc promote the supplement for anti-inflammatory support of the immune system. This is potentially helpful for a variety of conditions.
"Alzheimer's disease, Parkinson's disease, autism, epilepsy, schizophrenia - things that we never before had any idea what the etiology of the disease could be. Heart disease, diabetes, arthritis, inflammatory disease of the bowels like Crohn's disease, [the list goes] on and on. And one of the most intriguing deceases is fibromyalgia," said Dr. Wilson.
Anatabloc, which comes in pill or lozenge form, is based on a substance called "Anatabine" that is found in tobacco plants.
That's right tobacco. After you take a pill, it enters your body and interacts with a protein in your cells.
The resulting cell adopts a natural anti-inflammatory process in the body. Researchers say it's very effective and promising in the battle against chronic pain.
"The inflammation is gone which helps the Crohn's," Reilly said.
Dr. Wilson explains further, "Anatabloc turns that chronic low grade inflammation off. That's why people with Crohn's disease, fibromyalgia show a marked response. From what I have been doing clinically, from what I've seen, that's one of its most effective areas.
Right now you can only purchase Anatabloc online on the company's website. A box contains 10 containers, each holding 20 tablets. One box is being sold for just under $100.
While the manufacturer touts Anatabloc as revolutionary against chronic inflammation, some researchers say it's a bit premature to reach that conclusion.
...None of that matters right now to Cheryl Reilly. She has a new career and is out enjoying life again - pain free.
"Oh my gosh, yes, I'm always excited about life everybody wonders why I'm always so happy," Reilly said. "It's just limitless, it's so exciting! It's just amazing."
There is still time to get involved with the clinical trials if you have ten weeks to devote to the study. Just call the office of Dr. Dale Wilson at 810-342-1725 to get started.
Anatabloc: "I am certain that my success is in part due to anatabloc." "I have an autoimmune disease, dermatomyositis, which can be quite serious. I was having joint pain throughout my body severe enough to limit movement. I also had the characteristic dermatomyositis skin rash. I began taking anatabloc on the recommendation of my internist, and my pain and rash began to resolve within 3 - 4 days. I stopped the anatabloc at one point because I thought it could not possibly be source of my improvement; after all, if a supplement could do that, wouldn't my rheumatologist know about it? After stopping the anatabloc, the pain and rash increased the next day, and continued to increase, until I resumed the anatabloc. After resuming the anatabloc, the symptoms once again began to resolve. If it can do this for me, surely it can help others who struggle with musculoskeletal pain. I am also on a very rigid plant based diet (as described in the book "Eat To Live", which I heartily recommend.) I suspect that the anatabloc has maximum beneficial effect because I am not eating a diet of processed foods. Others may not have found it beneficial because of the confounding effects of a generally unhealthy diet. I will add, after two months on anatabloc, I ceased taking Plaquenil, which my rheumatologist had prescribed to manage my autoimmune symptoms. With the benefit of anatabloc and a healthy diet, I felt there was a good chance I could do well off meds. Indeed, I am doing fine. My lab values are excellent. I am certain that my success is in part due to anatabloc." By Leesa Scott-morrow